Lipocine Inc. (LPCN): Price and Financial Metrics
GET POWR RATINGS... FREE!
LPCN Stock Summary
- For LPCN, its debt to operating expenses ratio is greater than that reported by only 0.44% of US equities we're observing.
- With a year-over-year growth in debt of -100%, LIPOCINE INC's debt growth rate surpasses only 0% of about US stocks.
- Over the past twelve months, LPCN has reported earnings growth of 2,390.3%, putting it ahead of 99.23% of US stocks in our set.
- Stocks that are quantitatively similar to LPCN, based on their financial statements, market capitalization, and price volatility, are TMBR, ATNM, BLDP, AGLE, and MCRB.
- LPCN's SEC filings can be seen here. And to visit LIPOCINE INC's official web site, go to www.lipocine.com.
LPCN Valuation Summary
- In comparison to the median Healthcare stock, LPCN's EV/EBIT ratio is 139.69% lower, now standing at -2.6.
- Over the past 114 months, LPCN's EV/EBIT ratio has gone up 2056.2.
Below are key valuation metrics over time for LPCN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LPCN | 2023-03-17 | 61.6 | 0.9 | -2.9 | -2.6 |
| LPCN | 2023-03-16 | 59.8 | 0.8 | -2.8 | -2.5 |
| LPCN | 2023-03-15 | 54.6 | 0.8 | -2.5 | -2.3 |
| LPCN | 2023-03-14 | 60.4 | 0.8 | -2.8 | -2.5 |
| LPCN | 2023-03-13 | 67.4 | 0.9 | -3.1 | -2.9 |
| LPCN | 2023-03-10 | 54.4 | 0.8 | -2.5 | -2.2 |
LPCN Growth Metrics
- Its 2 year cash and equivalents growth rate is now at -71.53%.
- Its 2 year price growth rate is now at 18.21%.
- The 3 year cash and equivalents growth rate now stands at -56.64%.
The table below shows LPCN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 16.58584 | -1.135365 | 4.095298 |
| 2022-06-30 | 16.64084 | -4.917978 | 3.423166 |
| 2022-03-31 | 16.14084 | -4.234931 | -0.754098 |
| 2021-12-31 | 16.14084 | -4.411303 | -0.634399 |
| 2021-09-30 | 0.054994 | -17.08987 | -17.7697 |
| 2021-06-30 | 0 | -14.27264 | -19.00166 |
LPCN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- LPCN has a Quality Grade of D, ranking ahead of 21.42% of graded US stocks.
- LPCN's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
- ZTS, MDWD, and GERN are the stocks whose asset turnover ratios are most correlated with LPCN.
The table below shows LPCN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.000 | NA | -1.022 |
| 2021-03-31 | 0.000 | NA | -1.500 |
| 2020-12-31 | 0.000 | NA | -4.723 |
| 2020-09-30 | 0.000 | NA | -3.288 |
| 2020-06-30 | 0.008 | 1 | -2.946 |
| 2020-03-31 | 0.008 | 1 | -1.844 |
LPCN Price Target
For more insight on analysts targets of LPCN, see our LPCN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.75 | Average Broker Recommendation | 1.33 (Strong Buy) |
LPCN Stock Price Chart Interactive Chart >
LPCN Price/Volume Stats
| Current price | $0.30 | 52-week high | $1.89 |
| Prev. close | $0.31 | 52-week low | $0.27 |
| Day low | $0.29 | Volume | 440,500 |
| Day high | $0.32 | Avg. volume | 175,200 |
| 50-day MA | $0.47 | Dividend yield | N/A |
| 200-day MA | $0.54 | Market Cap | 26.32M |
Lipocine Inc. (LPCN) Company Bio
Lipocine develops pharmaceutical products using its oral drug delivery technology in the areas of mens and womens health, with a current focus being testosterone replacement. The company was founded in 1997 and is based in Salt Lake City, Utah.
Latest LPCN News From Around the Web
Below are the latest news stories about LIPOCINE INC that investors may wish to consider to help them evaluate LPCN as an investment opportunity.
LPCN: 2022 Operational & Financial UpdateBy John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 2022 was an eventful year for Lipocine Inc (NASDAQ:LPCN) with both product and strategy achievements. The company’s first developed product, Tlando, launched in 2022 following a March 2022 FDA approval. Other material events in the year include the shift in strategy to focus on the development of treatments for central |
Lipocine Announces Financial Results for the Year Ended December 31, 2022Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the year ended December 31, 2022 and provided a corporate update. |
Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common StockLipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on March 24, 2023. The shares of Series B Preferred Stock will be distributed to such recipients at 5:00 p.m |
Is Lipocine Inc.'s (NASDAQ:LPCN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?Lipocine (NASDAQ:LPCN) has had a great run on the share market with its stock up by a significant 31% over the last... |
Lipocine to Present at Biotech ShowcaseLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary platform to develop differentiated products, today announced that its management will present at the Biotech Showcase and host institutional investor and partnering meetings at this event and a Corporate Access Event organized by LifeSci Partners. Both in-person events will take place January 9-11, 2023, in San Francisco, California. |
LPCN Price Returns
| 1-mo | -36.17% |
| 3-mo | -26.05% |
| 6-mo | -39.58% |
| 1-year | -83.78% |
| 3-year | -25.74% |
| 5-year | -81.25% |
| YTD | -24.59% |
| 2022 | -59.86% |
| 2021 | -27.13% |
| 2020 | 253.34% |
| 2019 | -70.39% |
| 2018 | -62.21% |
Loading social stream, please wait...